118 related articles for article (PubMed ID: 35230704)
1. Morphea and COVID-19 mRNA vaccine.
Sookaromdee P; Wiwanitkit V
Int J Dermatol; 2022 May; 61(5):e162. PubMed ID: 35230704
[No Abstract] [Full Text] [Related]
2. A case of morphea following the COVID-19 mRNA vaccine: on the basis of viral spike proteins.
Metin Z; Celepli P
Int J Dermatol; 2022 May; 61(5):639-641. PubMed ID: 35073411
[No Abstract] [Full Text] [Related]
3. Generalized morphea following the COVID vaccine: A series of two patients and a bibliographic review.
Antoñanzas J; Rodríguez-Garijo N; Estenaga Á; Morelló-Vicente A; España A; Aguado L
Dermatol Ther; 2022 Sep; 35(9):e15709. PubMed ID: 35811413
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis.
Faissner S; Richter D; Ceylan U; Schneider-Gold C; Gold R
J Neurol; 2022 Apr; 269(4):1774-1775. PubMed ID: 34435250
[No Abstract] [Full Text] [Related]
5. Newly-developed vitiligo following COVID-19 mRNA vaccine.
Uğurer E; Sivaz O; Kıvanç Altunay İ
J Cosmet Dermatol; 2022 Apr; 21(4):1350-1351. PubMed ID: 35152540
[No Abstract] [Full Text] [Related]
6. COVID-19 mRNA vaccine safety, immunogenicity, and effectiveness in a hospital setting: confronting the challenge.
Sultana J; Caci G; Hyeraci G; Albano L; Gianfredi V
Intern Emerg Med; 2022 Mar; 17(2):325-327. PubMed ID: 35084646
[No Abstract] [Full Text] [Related]
7. A Case of Morphea After COVID-19 Vaccination.
Sharma A; Sandhu A
Dermatitis; 2024; 35(2):187-188. PubMed ID: 37610869
[No Abstract] [Full Text] [Related]
8. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
Wang M; Wen W; Zhou M; Wang C; Feng ZH
Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268
[No Abstract] [Full Text] [Related]
9. Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
Stellini R; Gianello R; Meloni A; Croce E; Materzanini P; Gomarasca W
Infection; 2022 Jun; 50(3):791-793. PubMed ID: 34855188
[No Abstract] [Full Text] [Related]
10. COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease.
Spiera E; Agrawal M; Ungaro RC
Gastroenterology; 2022 Mar; 162(3):987-988. PubMed ID: 34626602
[No Abstract] [Full Text] [Related]
11. Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
Maeda M; Isawa T; Tada N
Circ J; 2022 Mar; 86(4):724. PubMed ID: 34866122
[No Abstract] [Full Text] [Related]
12. Erythroderma related with the first dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine in a patient with psoriasis.
Durmus O; Akdogan N; Karadag O; Gokoz O
Dermatol Ther; 2022 May; 35(5):e15363. PubMed ID: 35133700
[No Abstract] [Full Text] [Related]
13. Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre.
Koumaki D; Krueger-Krasagakis SE; Papadakis M; Katoulis AC; Gkiaouraki I; Zografaki K; Mylonakis D; Krasagakis K
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e411-e415. PubMed ID: 35075691
[No Abstract] [Full Text] [Related]
14. COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Parker C; Thompson D; Panchanathan SS; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(35):1115-1120. PubMed ID: 36048728
[No Abstract] [Full Text] [Related]
15. Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.
Gallagher MC; Haessler S; Pecoy-Whitcomb E; Bayuk J
Allergy Asthma Proc; 2022 Jan; 43(1):37-39. PubMed ID: 34983708
[No Abstract] [Full Text] [Related]
16. Generalized morphea after COVID-19 vaccines: a case series.
Paolino G; Campochiaro C; Di Nicola MR; Mercuri SR; Rizzo N; Dagna L; Rongioletti F; De Luca G
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e680-e682. PubMed ID: 35604052
[No Abstract] [Full Text] [Related]
17. Delayed angioedema after administration of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine.
Watts MM; Maurer LE; Grammer LC; Saltoun CA; Stevens WW
Ann Allergy Asthma Immunol; 2022 Feb; 128(2):215-216. PubMed ID: 34699970
[No Abstract] [Full Text] [Related]
18. Incidence of Myocarditis after Messenger RNA Vaccine for COVID-19 in Young Male Recipients.
Kato S; Horita N; Utsunomiya D
Am J Cardiol; 2022 Jun; 172():159-161. PubMed ID: 35339272
[No Abstract] [Full Text] [Related]
19. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
Masset C; Benotmane I; Dantal J; Garandeau C; Gauthier-Vargas G; Cantarovich D; Meurette A; Giral M; Caillard S; Blancho G
Kidney Int; 2022 Apr; 101(4):825-826. PubMed ID: 35167873
[No Abstract] [Full Text] [Related]
20. Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review.
Pauluzzi M; Stinco G; Errichetti E
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e257-e259. PubMed ID: 34928518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
